Our collaboration with Dr. Moore. If human results strategy our animal results, we might be able to present an immunotherapy that is less expensive, more effective and ideal for use to the induction of chemical castration of prostate cancers patients prior. .. Advaxis advances business lead prostate tumor immunotherapeutic toward clinical trials Advaxis, Inc., . Advaxis, the live, attenuated Listeria monocytogenes immunotherapy company, is advancing the scientific development of its business lead prostate tumor immunotherapeutic toward clinical trials.Zakour, PhD, executive director of The Tech Council of Maryland/MdBio.. Acceleron presents RAP-661 preclinical data in osteopenic mice in international meeting Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, offered preclinical data highlighting the significant anabolic bone effects in osteopenic and normal mice of RAP-661. Treatment with the investigational substance showed improved bone mineral density, increased osteoblast activity and reduced osteoclast activity. Aaron Mulivor, Ph.D.